Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13713969 | 1.00 | PDE3A (0.62) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL19932385 | 1.00 | PDE3A (0.62) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL6153492 | 0.89 | PDE3A (0.61) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL13487257 | 0.88 | PDE3A (0.60) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL15189232 | 0.88 | PDE3A (0.60) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL13813007 | 0.88 | PDE3A (0.60) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL14180581 | 0.88 | PDE3A (0.60) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL18270531 | 0.86 | PDE3A (0.49) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL24735360 | 0.85 | PDE3A (0.50) | PDE3APDE4DSLC29A1LMNACACNA1F | |
| SCHEMBL26247475 | 0.85 | PDE3A (0.50) | PDE3APDE4DSLC29A1LMNACACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121566-A1 | PROCESS FOR PREPARING CEDAZURIDINE | SCINOPHARM SINGAPORE PTE LTD. (SG) | 2023-06-29 | — | — | WO | disclosed |
| EP-3947408-B1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023072043-A1 | COMBINED DRUG FOR TREATING TUMORS | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2020223530-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-3730508-A1 | LIVER SPECIFIC DELIVERY-BASED GEMCITABINE PRODRUG NUCLEOSIDE CYCLIC PHOSPHATE COMPOUND, AND APPLICATION THEREOF | Zhejiang Palo Alto Pharmaceuticals, Inc (CN) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020201751-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020041051-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041050-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019152911-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-7803785-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1864683-B1 | RADIOTHERAPY ENHANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090281105-A1 | RADIOTHERAPY ENHANCER | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7608602-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080275071-A1 | Radiotherapy Enhancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1864683-A1 | RADIOTHERAPY ENHANCER | Taiho Pharmaceutical Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-7265096-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, GDA, GCG | PDE3A 542/4885PDE4D 974/4885SLC29A1 41/4885 |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | NUDT1, NTPCR, ENTPD5 | PDE3A 698/4885PDE4D 278/4885SLC29A1 27/4885 |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | TYMP, GDA, GCG | PDE3A 542/4885PDE4D 974/4885SLC29A1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.